Pulmotect's PUL-042, an inhaled immunomodulatory agent to prevent and treat coronavirus and other respiratory infections was delivered successfully by PARI's LC Sprint Reusable Nebulizer
PARI's LC Sprint Nebulizer and Filter Valve Set. (Credit: PRNewswire / PARI Respiratory Equipment, Inc.)
Pulmotect reported positive results from their second randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with inhaled PUL-042 had positive efficacy signals for prevention and treatment of COVID-19, improvement of respiratory symptoms and fewer intensive care unit admissions, in addition to potential activity against all SARS-CoV-2 Variants.
Pulmotect’s PUL-042, an inhaled immunomodulatory agent to prevent and treat coronavirus and other respiratory infections was delivered successfully by PARI’s LC Sprint Reusable Nebulizer. PARI’s nebulizer devices have a proven record with pharmaceutical companies for efficient delivery of new pharmaceutical agents to the lungs.
“We observed further indications of clinical activity from our double blind, randomized, placebo-controlled Phase 2 clinical trial in subjects exposed to SARS-CoV-2, said Colin Broom, MD, Chief Executive Officer of Pulmotect. PUL-042 was administered by nebulization on Day 1, Day 3, Day 6 and Day 10 following enrollment into this trial with follow up to Day 29. These data in conjunction with the previously reported trial in patients with early COVID-19 are consistent with the demonstration in multiple animal models of the ability of PUL-042 to stimulate the immune system in the lungs to protect against a wide range of pathogens.”
“We are delighted with Pulmotect’s achievements and the performance of PARI’s LC Sprint Nebulizer in the Phase 2 studies. We are pleased to provide our clinically proven nebulizers for these important studies” stated Geoff A. Hunziker, President of PARI Respiratory Equipment, Inc. “The results of the PUL-042 program are very encouraging to support a potential treatment option to reduce the severity of COVID-19.”, said Lisa Cambridge, MSHS, RRT, Director of Medical Science at PRE Holding, Inc.
Source: Company Press Release